Skip to main content
SpringerLink
Log in

Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: Impact of tumour site, patient age and magnesium suppletion

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

In a group of ten patients, treated with cisplatin for advanced or metastatic urothelial cancer, renal function deteriorated in six. In a group of 28 patients, treated with cisplatin for tumours outside the urinary tract, renal function was impaired in 14 (50%). Renal function deterioration occurred more frequently in later life.

Localization of the primary tumour in the urinary tract does not seem to predispose to renal function impairment.

In contrast with reports in the literature, there was a significant decrease in serum calcium levels in spite of magnesium suppletion and normal serum magnesium levels. These calcium levels spontaneously returned to normal some months after the last treatment course with cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yagoda, A.: Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer.Cancer Res., 37, 2775 (1977).

    PubMed  Google Scholar 

  2. Soloway, M. S., Ikard, M., Ford, K.: Cis-diaminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer.Cancer, 47, 476 (1981).

    PubMed  Google Scholar 

  3. Merrin, C. E.: Treatment of genitourinary tumours with cis-Dichlorodiamineplatinum(II): experience in 250 patients.Cancer Treat. Rep., 63, 1579 (1979).

    PubMed  Google Scholar 

  4. Von Hoff, D. D., Schilsky, R., Reichert, C. M., Reddick, R. L., Rozencweig, M., Young, R. C., Muggia, F. M.: Toxic effects of cis-Dichlorodiamineplatinum(II) in man.Cancer Treat. Rep., 63, 1527 (1979).

    PubMed  Google Scholar 

  5. Blachle, J. D., Hill, J. B.: Renal and electrolyte disturbances associated with Cisplatin.Ann. Int. Med., 95, 628 (1981).

    PubMed  Google Scholar 

  6. Hayes, F. A., Green, A. A., Senzer, N., Pratt, C. B.: Tetany: a complication of cis-Dichlorodiamineplatinum(II) therapy.Cancer Treat. Rep., 63, 547 (1979).

    PubMed  Google Scholar 

  7. Gonzalez-Vitale, J. C., Hayes, D. M., Cvitkovic, E., Sternberg, S. S.: The renal pathology in clinical trials of cis Platinum(II)diaminedichloride.Cancer, 39, 1362 (1977).

    PubMed  Google Scholar 

  8. Comis, R. L.: Cisplatin nephrotoxicity: the effect of dose, schedule and hydration scheme. In: Prestayko, A. W., Cook, S. T., Carter, S. K. (eds): Cisplatin, Current Status and New Developments. Academic Press, New York 1980, p. 36.

    Google Scholar 

  9. Weiss, R. B., Poster, D. S.: The renal toxicity of cancer chemotherapeutic agents.Cancer Treat. Rev., 9, 37 (1982).

    PubMed  Google Scholar 

  10. Rossof, A. H., Slayton, R. E., Perlia, C. P.: Preliminary clinical experience with cis-Diaminedichloroplatinum(II).Cancer, 30, 1451 (1972).

    PubMed  Google Scholar 

  11. Krakoff, I. H.: Nephrotoxicity of cis-Dichlorodiamineplatinum(II).Cancer Treat. Rep., 63, 1523 (1979).

    PubMed  Google Scholar 

  12. Editorial. Cisplatin.Lancet, 1 (8268), 374 (1982).

  13. Aapro, M. S.: Effects and side-effects of Cisplatin.Lancet, 1 (8273) 682 (1982).

    PubMed  Google Scholar 

  14. Cohen, A. I., Harberg, J., Citrin, D. L.: Measurement of urinary β2-microglobulin in the detection of Cisplatin nephrotoxicity.Cancer Treat. Rep., 65, 1083 (1981).

    PubMed  Google Scholar 

  15. Jones, B. R., Bhalla, R. B., Mladek, J., Kaleya, R. N., Gralla, R. J., Alcock, N. W., Schwartz, M. K., Young, C. W., Reidenberg, M. M.: Comparison of methods of evaluating nephrotoxicity of cis-Platinum.Clin. Pharmacol. Ther., 27, 557 (1980).

    PubMed  Google Scholar 

  16. Hrushesky, W. J. M., Shimp, W., Kennedy, B. J.: Lack of age-dependent Cisplatin nephrotoxicity.Am. J. Med., 76, 579 (1984).

    PubMed  Google Scholar 

  17. Bitran, J. D., Desser, R. K., Billings, A. A., Kozloff, M. F., Shapiro, C. M.: Acute nephrotoxicity following Cis-dichlorodiamine-platinum.Cancer, 49, 1784 (1982).

    PubMed  Google Scholar 

  18. Lyman, N. W., Hemalatha, C., Viscuso, R. L., Jacobs, M. G.: Cisplatin-induced hypocalcaemia and hypomagnesaemia.Arch. Int. Med., 140, 1513 (1980).

    Google Scholar 

  19. Macaulay, V. M., Begent, R. H. J., Phillips, M. E., Newlands, E. S.: Prophylaxis against hypomagnesaemia induced by cis-Platinum combination therapy.Cancer Chemother. Pharmacol., 9, 179 (1982).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Erasmus University, Rotterdam, The Netherlands

    J. H. M. Blom & K. H. Kurth

  2. Department of Internal Medicine, Division of Medical Oncology, Erasmus University, Rotterdam, The Netherlands

    T. A. W. Splinter

Authors
  1. J. H. M. Blom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. H. Kurth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. A. W. Splinter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blom, J.H.M., Kurth, K.H. & Splinter, T.A.W. Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: Impact of tumour site, patient age and magnesium suppletion. International Urology and Nephrology 17, 331–339 (1985). https://doi.org/10.1007/BF02083503

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02083503

Keywords

Search

Navigation